http://seekingalpha.com/article/1329491-tech-and-healthcare-eye-catching-themes-of-early-april?source=yahoo
"A more recent example of the effects of the patent cliff can be seen with the hype MannKind (MNKD) has received; as its ultra-fast inhalable insulin, Afrezza, is preparing for a third FDA submission. Afrezza would offer any player in the diabetes field an alternative treatment that would extend patent portfolio ensuring the potential buyer a competitive product and steady revenue stream for years to come. In 2013, MNKD has experienced a 57% surge in its stock price in hope of finally receiving FDA approval sometime in 2014. Obviously, approval to market in the U.S. would have the big pharmas lining up at Mr. Mann's door with partnership deals worth billions. This fact alone is giving investors a reason to be speculating with the future of this potentially breakthrough diabetic drug"
OOG
